The Slovak company developing a state-of-the-art cancer diagnosis Multiplex9 was awarded the prestigious Seal of Excellence certificate.
This quality-label is awarded by the European Commission under Horizon 2020 program for research and innovation. A team of independent experts deemed the company to be top-notch and to deserve funding. This evaluation significantly increases its chances to receive a €2.8M funding in the next round.
"For us, this is a proof that our project, business plan, commercial strategies, and the team are very innovative and prone to success. We've now reached the last phase of fundraising and we will soon begin the next stage of development," said Pavol Čekan, the company's CEO. More.
Last week, the renowned magazines Forbes and DenníkN looked at what makes MultiplexDX unique, who are the people behind it and what will be their next steps towards developing the perfect cancer diagnostics.